GENLISA™ SARS-CoV-2 (Covid-19) Neutralizing Antibody ELISA

ELISA for the Quantitative determination of neutralizing antibody to the SARS-CoV-2 receptor binding domain (RBD) of its spike protein in human serum and plasma samples. Also known as the sVNT assay. CE IVD marked. This assay has been calibrated against NIBSC / WHO international standards for COVID-19. The kit can be used for qualitative or quantitative estimation. Species and isotype independent with low-to-no cross reactivity with the flu and other viral diseases. Detecting and quantifying neutralizing antibodies to SARS-CoV-2 offers important information in the evaluation of immune responses, development of vaccines and therapeutic drugs. The kit employs a blocking ELISA technique which mimics the virus neutralization process. Potent neutralizing antibodies often target the receptor interaction site in S1, disabling receptor interactions. The spike proteins of SARS-CoV-2 commonly bind to the human angiotensin converting enzyme 2 (ACE2) protein as a host receptor through their S1B domain. Receptor interaction is known to trigger irreversible conformational changes in coronavirus spike proteins enabling membrane fusion. SARS-CoV-2 initiates an immune response, which leads to the production of antibodies. These neutralizing antibodies disable host receptor interactions and prevent viral entry into the cell. They, therefore, also provide protection against future infection from SARS-CoV-2, as they remain in the circulatory system for months to years post infection.